Literature DB >> 17224214

Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people.

M Feyssaguet1, L Dacheux, L Audry, A Compoint, J L Morize, I Blanchard, H Bourhy.   

Abstract

The envelope glycoprotein G of rabies virus induces the production of neutralising antibodies, which are important in protection against rabies. Therefore, titration of anti-envelope glycoprotein antibodies is a good indicator of the degree of immunity in people during anti-rabies treatment or after vaccination. According to the World Health Organization (WHO) guidelines, a booster vaccine dose should be given if the rabies antibody titre falls below 0.5 IU/ml. Titration of anti-rabies antibodies is also useful for plasma centers in the preparation and standardization of human anti-rabies gamma-globulins for therapeutic use and to a lesser extent for the diagnosis of rabies in human sera and cerebrospinal fluid (CSF). This paper presents a new enzyme-linked immunosorbent assay (ELISA), PLATELIA RABIES II, developed for rabies envelope glycoprotein antibody detection or titration and its comparison to the current reference method (RFFIT). The data collected during validation of the test in a multicenter study are analysed to give a sound overall knowledge of the capabilities of the PLATELIA RABIES II, for instance specificity, linearity, accuracy, precision, detection limit and quantitation limit. To this aim, human serum samples from a total of 1348 vaccinated or non-vaccinated people were tested in parallel using the new ELISA and the RFFIT for the presence of anti-rabies antibodies. Data generated indicate a linear relationship across the range of titration between the two methods. The sensitivity reaches 98.6% and the specificity 99.4%. This study indicates that this new ELISA test is as sensitive and specific as the current standardized reference method. The method is simple, safe, rapid and can be considered as a useful alternative to the neutralisation test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17224214     DOI: 10.1016/j.vaccine.2006.12.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation.

Authors:  Lihong Tao; Jinying Ge; Xijun Wang; Hongyue Zhai; Tao Hua; Bolin Zhao; Dongni Kong; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Highly efficient production of rabies virus glycoprotein G ectodomain in Sf9 insect cells.

Authors:  Alexandra Marisa Targovnik; Alejandro Ferrari; Gregorio Juan Mc Callum; Mariana Bernadett Arregui; Ignacio Smith; Lautaro Fidel Bracco; Victoria Alfonso; María Gabriela López; María Martínez-Solís; Salvador Herrero; María Victoria Miranda
Journal:  3 Biotech       Date:  2019-10-04       Impact factor: 2.406

3.  Optimization and validation of a blocking ELISA for quantitation of anti-rabies immunoglobulins in multispecies sera.

Authors:  Diego Fontana; María Celeste Rodriguez; Ernesto Garay; Susana Russo; Claudio Prieto
Journal:  Appl Microbiol Biotechnol       Date:  2020-03-13       Impact factor: 4.813

4.  Virology, immunology and pathology of human rabies during treatment.

Authors:  Yolanda Caicedo; Andres Paez; Ivan Kuzmin; Michael Niezgoda; Lillian A Orciari; Pamela A Yager; Sergio Recuenco; Richard Franka; Andres Velasco-Villa; Rodney E Willoughby
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

5.  Diagnosis and molecular characterization of rabies virus from a buffalo in China: a case report.

Authors:  Ke-Shan Zhang; Jian-Hong Guo; Zhuo-Fei Xu; Min Xiang; Bin Wu; Huan-Chun Chen
Journal:  Virol J       Date:  2011-03-06       Impact factor: 4.099

Review 6.  Detection and quantification of anti-rabies glycoprotein antibodies: current state and perspectives.

Authors:  Maria Celeste Rodriguez; Diego Fontana; Ernesto Garay; Claudio Prieto
Journal:  Appl Microbiol Biotechnol       Date:  2021-08-27       Impact factor: 4.813

Review 7.  More accurate insight into the incidence of human rabies in developing countries through validated laboratory techniques.

Authors:  Laurent Dacheux; Supaporn Wacharapluesadee; Thiravat Hemachudha; François-Xavier Meslin; Philippe Buchy; Jean-Marc Reynes; Hervé Bourhy
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

8.  Rabies Risk: Difficulties Encountered during Management of Grouped Cases of Bat Bites in 2 Isolated Villages in French Guiana.

Authors:  Franck Berger; Noëlle Desplanches; Sylvie Baillargeaux; Michel Joubert; Manuelle Miller; Florence Ribadeau-Dumas; André Spiegel; Hervé Bourhy
Journal:  PLoS Negl Trop Dis       Date:  2013-06-27

9.  Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine.

Authors:  Xinjian Liu; Hong Lin; Qi Tang; Chen Li; Songtao Yang; Zhongcan Wang; Changjun Wang; Qing He; Brian Cao; Zhenqing Feng; Xiaohong Guan; Jin Zhu
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

10.  A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods.

Authors:  Mary J Warrell; Anna Riddell; Ly-Mee Yu; Judith Phipps; Linda Diggle; Hervé Bourhy; Jonathan J Deeks; Anthony R Fooks; Laurent Audry; Sharon M Brookes; François-Xavier Meslin; Richard Moxon; Andrew J Pollard; David A Warrell
Journal:  PLoS Negl Trop Dis       Date:  2008-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.